These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38360636)

  • 1. Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.
    Scheffges C; Devy J; Giustiniani J; Francois S; Cartier L; Merrouche Y; Foussat A; Potteaux S; Bensussan A; Marie-Cardine A
    Breast Cancer Res; 2024 Feb; 26(1):28. PubMed ID: 38360636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
    El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
    J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible pathogenic role of the transmembrane isoform of CD160 NK lymphocyte receptor in paroxysmal nocturnal hemoglobinuria.
    Giustiniani J; Alaoui SS; Marie-Cardine A; Bernard J; Olive D; Bos C; Razafindratsita A; Petropoulou A; de Latour RP; Le Bouteiller P; Bagot M; Socié G; Bensussan A
    Curr Mol Med; 2012 Feb; 12(2):188-98. PubMed ID: 22172098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation.
    Giustiniani J; Bensussan A; Marie-Cardine A
    J Immunol; 2009 Jan; 182(1):63-71. PubMed ID: 19109136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma.
    Gauci ML; Giustiniani J; Lepelletier C; Garbar C; Thonnart N; Dumaz N; Foussat A; Lebbé C; Bensussan A; Marie-Cardine A
    Cancer Immunol Immunother; 2022 Nov; 71(11):2731-2742. PubMed ID: 35428910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
    Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human and mouse mast cells express and secrete the GPI-anchored isoform of CD160.
    Ortonne N; Ram-Wolff C; Giustiniani J; Marie-Cardine A; Bagot M; Mecheri S; Bensussan A
    J Invest Dermatol; 2011 Apr; 131(4):916-24. PubMed ID: 21191401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.
    Roberti MP; Juliá EP; Rocca YS; Amat M; Bravo AI; Loza J; Coló F; Loza CM; Fabiano V; Maino M; Podhorzer A; Fainboim L; Barrio MM; Mordoh J; Levy EM
    Eur J Immunol; 2015 May; 45(5):1560-9. PubMed ID: 25726929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
    Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
    Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer.
    Del Bano J; Florès-Florès R; Josselin E; Goubard A; Ganier L; Castellano R; Chames P; Baty D; Kerfelec B
    Front Immunol; 2019; 10():1593. PubMed ID: 31354732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A Preliminary Study on the Expression of CD160 on NK Cells and Its Mechanism of Mediating NK Killing Effect].
    Wang ZH; Liu HH; Ma N; Wang LH; Liu W; Tang B; Qiu ZX; Cen XN; Ren HY; Dong YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1559-1564. PubMed ID: 30295284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
    Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
    Front Immunol; 2018; 9():2140. PubMed ID: 30294328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD160: a unique activating NK cell receptor.
    Le Bouteiller P; Tabiasco J; Polgar B; Kozma N; Giustiniani J; Siewiera J; Berrebi A; Aguerre-Girr M; Bensussan A; Jabrane-Ferrat N
    Immunol Lett; 2011 Aug; 138(2):93-6. PubMed ID: 21324341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
    Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
    Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD160 receptor in CLL: Current state and future avenues.
    Oumeslakht L; Aziz AI; Bensussan A; Ben Mkaddem S
    Front Immunol; 2022; 13():1028013. PubMed ID: 36420268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD160 is essential for NK-mediated IFN-γ production.
    Tu TC; Brown NK; Kim TJ; Wroblewska J; Yang X; Guo X; Lee SH; Kumar V; Lee KM; Fu YX
    J Exp Med; 2015 Mar; 212(3):415-29. PubMed ID: 25711213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.
    Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI
    Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity.
    Giustiniani J; Marie-Cardine A; Bensussan A
    J Immunol; 2007 Feb; 178(3):1293-300. PubMed ID: 17237375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of CD160 in natural killer (NK) cells from patients with active tuberculosis and its relationship with cell functions].
    Yang B; Zhai F; An H; Cao Z; Liu Y; Wang R; Cheng X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Oct; 38(10):918-924. PubMed ID: 36163624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset.
    Barakonyi A; Rabot M; Marie-Cardine A; Aguerre-Girr M; Polgar B; Schiavon V; Bensussan A; Le Bouteiller P
    J Immunol; 2004 Nov; 173(9):5349-54. PubMed ID: 15494480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.